THE-630

First Patient Treated With THE-630 in GIST Phase 1/2 Trial

The first patient with gastrointestinal stromal tumor (GIST) has been treated with the experimental drug THE-630 as part of an ongoing phase 1/2 clinical trial, according to a press release from Theseus Pharmaceuticals, the developers of the drug. “The initiation of our Phase 1/2 trial in patients with previously-treated advanced GIST is an important milestone…

New Pan-Variant KIT Inhibitor for GIST Gains FDA Clearance for Clinical Trials

THE-630, an investigational therapy for gastrointestinal stromal tumor (GIST), has gained US Food and Drug Administration (FDA) clearance for clinical trials to begin, according to Thesus Pharmaceuticals. THE-630 works as a pan-variant KIT inhibitor. In recent years, new therapies that treat GIST in a more targeted way have been developed and commercialized. One type of…

Next post in GIST News Briefs